Literature DB >> 2195275

[Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria)].

G Charmot1, J P Coulaud.   

Abstract

Chloroquine is currently the drug of choice for treatment of acute attacks of Plasmodium falciparum malaria in chloroquine-sensitive areas. In areas of low level resistance, this drug may still be used (25 mg/kg of body weight in three days) in semi-immune patients. In case of failure, or in areas of high level resistance, quinine (25 mg/kg/day for 3 to 5 days) or, in spite of increasing resistance, Fansidar should be prescribed. Mefloquine, Fansimef and Halofantrine ought to be strictly prescribed to delay occurrence of resistance. Severe attacks require quinine by continuous intravenous infusion. Spleen enlargement does not usually require specific treatment unless poor tolerance is observed. Blood transfusions present a considerable risk of HIV transmission. Appropriate malaria treatment may avoid blood transfusions thus preventing HIV dissemination in Africa.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195275

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  4 in total

1.  Chloroquine administration does not prevent Nipah virus infection and disease in ferrets.

Authors:  Jackie Pallister; Deborah Middleton; Gary Crameri; Manabu Yamada; Reuben Klein; Tim J Hancock; Adam Foord; Brian Shiell; Wojtek Michalski; Christopher C Broder; Lin-Fa Wang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

Review 2.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

3.  Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells.

Authors:  Mohsin Khan; S R Santhosh; Mugdha Tiwari; P V Lakshmana Rao; Manmohan Parida
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

4.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.

Authors:  Els Keyaerts; Leen Vijgen; Piet Maes; Johan Neyts; Marc Van Ranst
Journal:  Biochem Biophys Res Commun       Date:  2004-10-08       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.